Real World Efficacy and Safety of First Line Chemo Immunotherapy in Extensive Stage Small Cell Lung Cancer and its association with molecular subtype
In this real-world Korean cohort, first-line chemo-immunotherapy achieved outcomes comparable to pivotal trials, supporting its role as standard care for ES-SCLC in clinical practice.
Authors
- Jong‐Mu Sun (ORCID: https://orcid.org/0000-0001-9683-4111)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5740-9654)
- Se‐Hoon Lee (ORCID: https://orcid.org/0000-0002-9219-3350)
- Junkyu Kim (ORCID: https://orcid.org/0009-0001-4422-5434)
- Miran Han (ORCID: https://orcid.org/0000-0001-7752-5858)
- Jin Seok Ahn (ORCID: https://orcid.org/0000-0002-2880-6730)
- Jin‐Yong Kim (ORCID: https://orcid.org/0000-0002-5499-2581)
- Sehhoon Park (ORCID: https://orcid.org/0000-0001-9467-461X)
Institutions
- Samsung Medical Center (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-11-05
- DOI
- https://doi.org/10.4143/crt.2025.971
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Samsung